论文部分内容阅读
Imipenem(IPM)系硫霉素第一个高效衍生物,是新型的β-内酰胺类超广谱抗生素,对临床几乎所有重要致病菌均具有强大抗菌作用,对酶高度稳定,与其它抗菌药几乎无交叉耐药性,具有持续的抗生素后效作用(PAE),且体内分布广、不良反应少。IPM在体内经近端肾小管细胞刷状缘的去氢肽酶Ⅰ代谢灭活,其分解产物对某些动物肾小管有一定毒性反应。临床上将本品与肾去氢肽酶Ⅰ抑制剂Cilastatin按1∶1制成复方制剂(Primaxin或Tienam)应用,可阻断本品在肾脏的代谢和增加泌尿道中原型浓度,并消除其单用可能生产的肾毒性。IPM/Cilastatin在临床上经验治疗各种严重的多重耐药菌感染、多种细菌(需氧菌和厌氧菌)
Imipenem (IPM) is the first highly effective derivative of thiopene. It is a novel β-lactam broad-spectrum antibiotic that has strong antibacterial activity against almost all important pathogenic bacteria in clinical practice, is highly stable against enzymes, Drug almost no cross-resistance, with continuous antibiotic effect (PAE), and the body widely distributed, fewer adverse reactions. In vivo, IPM is metabolically inactivated by dehydropeptidase I at the brush border of proximal tubular cells, and its breakdown products have some toxicological effects on the renal tubules of some animals. Clinically, this product and renal dehydropeptidase Ⅰ inhibitor Cilastatin 1: 1 made of compound preparation (Primaxin or Tienam) application, can block the product metabolism in the kidney and increase urinary tract concentration, and eliminate the single With the possible production of nephrotoxicity. IPM / Cilastatin is clinically experienced in the treatment of various severe multi-drug resistant infections, multiple bacteria (aerobic and anaerobic bacteria)